Chiesi Farmaceutici S.p.a.

Roberto Bilzi

Daniela Cocconi

Paolo Chiesi

Paolo Ventura

Rossella Musa

Francesca Schiaretti

Rosella Musa

Angela Armanni

Roberto Rastelli

Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.

Dry powder formulation comprising a phosphodiesterase inhibitor

The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of low-dosage strength active ingredients to the low respiratory tract of patient. In particular, the invention provides a formulation comprising microparticles constituted of microparticles of a low-dosage strength active ingredient and microparticles of an excipient wherein the MMD of the microparticles is comprised between 2 and 15 micron, at least 10% of the microparticles has a mass diameter (MD) higher than 0.5 micron, and the process of preparation thereof.

Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient

The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.

Modified carrier particles for use in dry powder inhalers

Growing community of inventors

Parma, Italy

Roberto Bilzi